Business NewsEventsNews



When the NASDAQ Stock Market closing bell rang on May 28, it was AngioDynamics’s three most tenured employees who were doing the honors. The May 28 honor commemorated the company’s 15th anniversary on the exchange.


J. Clemmer

“NASDAQ has provided AngioDynamics with a robust platform to access the public equity markets and connect with potential shareholders and investors,” Jim Clemmer, president and CEO of AngioDynamics, said. Clemmer and the entire management team was on hand for the ceremony.

“Since going public over 15 years ago, we have grown almost 10-fold in revenue and are now driving future growth through focused, strategic choices in key therapeutic areas. We are making targeted investments aimed at advancing proprietary medical technologies, such as AngioVac, BioFlo and the NanoKnife System, all of which are addressing unmet patient needs.

“Every day, AngioDynamics’ talented and dedicated employees leverage their expertise in R&D and manufacturing to deliver medical technologies that support high-quality care, wellness and cures for people living with society’s most challenging diseases. We believe that these patients deserve to live healthier, happier lives, and we are making meaningful strides across all facets of our business in support of this core belief that we each share.

Three days later, AngioDynamics’ current fiscal year closed on May 31. It was a noteworthy year.


During the current fiscal year, the company completed the consolidation of two production facilities; acquired BioSentry Tract Sealant technology and RadiaDyne; and announced the divestiture of its NAMIC Fluid Management business.


Additionally, the company enrolled the first patient in its DIRECT Clinical Study for the treatment of Stage III pancreatic cancer and also received approval from the United States Food and Drug Administration to initiate a pilot study for the use of NanoKnife in the treatment of prostate cancer.

AngioDynamics is a provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease and oncology. VTN


Previous post

CVS still defending the Aetna merger deal 

Next post


Larry Storer

Larry Storer

Larry Storer has been editor of Vein Therapy News for 10 years. He has edited computer, shelter and medical publications at Publications & Communications LP for 30 years. He was also a corporate vice president and editorial director before retiring. Larry graduated from Baylor University with a BA in journalism and an MA in communications; and from Lamar University with a MED in school administration. He taught beginning and advanced reporting, beginning and advanced editing and editorial writing at Baylor University. Larry was a reporter, and city and news editor of the Beaumont Journal, and opinion editor at the Beaumont Enterprise and Beaumont Enterprise-Journal. He was also the founding managing editor of the Yuba City (California) Daily Independent-Herald.